Cadwalader, Wickersham & Taft LLP, a leading counselor to global financial institutions and corporations, announced today that client Elan Corporation, plc, a biotechnology company headquartered in Ireland, will purchase from Theravance, In...
03:48 PM EDT, 05/13/2013 (MidnightTrader) -- Top Healthcare Stocks JNJ -0.07% PFE +1.90% ABT +0.65% MRK +0.45% AMGN -0.11% Healthcare stocks are higher in late trade with the NYSE Healthcare Sector Index (^NYP) climbing 0.2% and the S&P Heal...
03:37 PM EDT, 05/13/2013 (MidnightTrader) -- Healthcare stocks are higher with the NYSE Healthcare Sector Index (^NYP) climbing 0.2% and the S&P Healthcare Index (^IXV) advancing 0.6%. In company news, Vivus Inc.(VVUS) is up 4.7% to $13.57 a sha...
12:37 PM EDT, 05/13/2013 (MidnightTrader) -- Top Healthcare Stocks JNJ +0.10% PFE +1.29% ABT +0.94% MRK +0.14% AMGN +0.41% Healthcare stocks are up, with the NYSE Healthcare Sector Index (^NYP) climbing 0.2% and the S&P Healthcare Index (^IX...
12:32 PM EDT, 05/13/2013 (MidnightTrader) -- Healthcare stocks are up, with the NYSE Healthcare Sector Index (^NYP) climbing 0.2% and the S&P Healthcare Index (^IXV) advancing 0.6%. In company news, Warner Chilcott plc (WCRX) is up 6.7% to $19.2...
12:19 PM EDT, 05/13/2013 (MidnightTrader) -- Theravance (THRX) shares are up more than 14% to $40.01 in mid-day trade, extending a pre-market surge and hitting a year high of $40.70, on news of a $1 billion royalty deal with drugmaker Elan (ELN)....
10:20 AM EDT, 05/13/2013 (MidnightTrader) -- Theravance (THRX) shares are holding pre-market gains of about 13% at $39.57 on $1 billion royalty pact with Elan (ELN) in which Elan will purchase a participation interest in potential future royalty ...
08:43 AM EDT, 05/13/2013 (MidnightTrader) -- Health care stocks: JNJ: +0.05% PFE: -0.07% ABT: flat MRK: -0.11% AMGN: -0.66% Healthcare shares are generally lower in pre-market trading, although Pluristem Therapeutic (PSTI) is up 3% at $3.0...
08:32 AM EDT, 05/13/2013 (MidnightTrader) -- Healthcare shares are generally lower in pre-market trading, although Pluristem Therapeutic (PSTI) is up 3% at $3.06 as it reports its PLacental eXpanded cells tested in preclinical animal models of pr...